Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2014

Rampias T, Giagini A, Siolos S, Matsuzaki H, Sasaki C, Scorilas A, Psyrri A

Abstract excerpt

PURPOSE: Cetuximab, an antibody directed against the EGF receptor, is an effective clinical therapy for patients with head and neck squamous cell cancer (HNSCC). Despite great clinical promise, intrinsic or acquired cetuximab resistance hinders successful treatment outcomes but little is known about the underlying mechanism. EXPERIMENTAL DESIGN: To study the role of oncogenic HRAS in cetuximab resistance in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Knock-In Techniques

Share to Head and Neck Neoplasms

Share to MAP Kinase Signaling System

Share to Microscopy, Confocal

Share to Receptor Cross-Talk

Share to Squamous Cell Carcinoma of Head and Neck

Source

Identifiers

PMID: 24696319
DOI: 10.1158/1078-0432.CCR-13-2721

Genes

HRAS
EGF
MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.PMID 24696319Read ↗

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.Semantic proximity Read ↗

Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck CancerSemantic proximity Read ↗

mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.Semantic proximity Read ↗

Is biomarker research advancing in the era of personalized medicine for head and neck cancer?Semantic proximity Read ↗

AXL Regulates Neuregulin1 Expression Leading to Cetuximab Resistance in Head and Neck CancerSemantic proximity Read ↗

EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.Semantic proximity Read ↗

Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCCSemantic proximity Read ↗

Molecular pathways in head and neck cancer: EGFR, PI3K, and more.Semantic proximity Read ↗

Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.Semantic proximity Read ↗

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapySemantic proximity Read ↗

New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors.Semantic proximity Read ↗

A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.